WhiteOak Capital Pharma and Healthcare Fund Regular-Growth
Equity
Sectoral-Pharma
₹1.25% 1D
NAV on
Overview
Chart
Returns
Asset Allocation
Fund Info
Risk & Return Ratio
Fund Overview
Rating
Not Rated
Minimum Investment
₹500
NAV (Net Asset Value)
₹N/A
AUM (Fund size)
₹793 Cr
Created on
2 Feb 2024
Fund Ranking
#
/ 15 in Sectoral-Pharma
Risk Level
Very High
Very High
Loading...
Returns
Trailing Return
Rolling Return
6 Month
23.7%
1 Year
17.6%
3 Year (CAGR)
-
All Time (CAGR)
22.1%
Category Return
6 Month
21.5%
1 Year
13.1%
3 Year (CAGR)
22.0%
All Time (CAGR)
-
Asset Allocation
Equity
92.6%
Debt
7.7%
Other
-0.3%
Top 5 Holdings
Top 5 Sectors
Apollo Hospitals Enterprise
4.24%
Apollo Hospitals Enterprise
0.32%
Astrazeneca Pharma India
1.07%
Aurobindo Pharma
3.02%
Aurobindo Pharma
2.03%
Fund Information
Expense Ratio
2.87%
Exit Load
No Exit Load
Lock-In Period
No Lock-In
Risk & Return Ratio
Sharpe Ratio
Sharpe Ratio evaluates a fund's return relative to its risk. Higher values signify better risk-adjusted performance.
0.00
Standard Deviation
Standard deviation measures the volatility of a fund's returns. The higher the value, the riskier the investment.
0.00
Alpha
Alpha in mutual funds measures excess return relative to a benchmark, indicating a manager's skill at generating returns beyond market performance.
0.00
Beta
Beta in mutual funds indicates a fund's sensitivity to market changes. A beta over 1 means it's more volatile than the market, while below 1 implies less volatility.